ArticleDrug development research2026
Solanaceae-Derived Spirostane Saponins Inhibit Dengue Virus Replication and Viral Protein Expression and Exhibit Activity Against Multiple Arboviruses.
Article in Drug development research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Mosquito-borne arboviruses, including dengue virus (DENV), Zika virus (ZIKV), and chikungunya virus (CHIKV), represent a growing global health burden, yet no specific antiviral therapies are currently available for most of these infections. This unmet need highlights the importance of identifying novel antiviral compounds from biologically relevant sources such as plant-derived natural products. In this study, a bioactivity-guided approach was applied to methanolic extracts from eight Solanaceae species to identify compounds with antiviral activity against DENV-2 in Vero cells. Five extracts significantly reduced viral infectivity, with Solanum ovalifolium and Cestrum sp. achieving complete inhibition at non-cytotoxic concentrations. Subsequent fractionation and purification led to the isolation of four spirostane-type steroidal saponins, structurally characterized by UPLC-DAD-MS and 1D/2D NMR spectroscopy. Functional assays demonstrated that these compounds inhibit DENV replication, as evidenced by marked reductions in viral RNA levels, NS1 and NS3 protein expression, and infectious viral titers. Stage-specific analyses revealed that their antiviral activity is primarily associated with intracellular phases of the viral life cycle, consistent with inhibition of viral replication and/or protein processing. Molecular docking analyses supported these findings by predicting favorable interactions with key viral enzymes, particularly NS5 RNA-dependent RNA polymerase and NS3 helicase/protease. Importantly, the isolated compounds retained antiviral activity against ZIKV and CHIKV, indicating cross-arboviral efficacy. Together, these findings identify spirostane saponins as promising antiviral scaffolds and support their further development as broad-spectrum antiviral agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.